A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR 652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV 1-Infected, Antiretroviral Treatment-Naive, Adult Patients With Only CCR5-Tropic Virus.

Trial Profile

A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR 652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV 1-Infected, Antiretroviral Treatment-Naive, Adult Patients With Only CCR5-Tropic Virus.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Cenicriviroc (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Biomarker; Therapeutic Use
  • Sponsors Tobira Therapeutics
  • Most Recent Events

    • 25 Feb 2016 Results of hepatic fibrosis biomarker analysis presented at the 23rd Conference on Retroviruses and Opportunistic Infections
    • 25 Feb 2016 Results assessing whether decreases in levels of sCD14 with cenicriviroc were attributable to decreased intestinal permeability and microbial translocation presented at the 23rd Conference on Retroviruses and Opportunistic Infections.
    • 08 Dec 2015 Results of post-hoc fibrosis scores analysis presented at HEP DART 2015, according to a Tobira Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top